Heart Failure

Moving away from the pay-per-pill standard, Novartis will attempt a new pricing model based on clinical outcomes for its widely anticipated chronic heart failure (HF) drug.

To win the health care relay race, one clinician needs to pass the baton to the next clinician, who must be ready to receive it.

High hospital readmission rates plague the health care system.

A study evaluating the cardiovascular safety of Merck's type 2 diabetes drug sitagliptin determined the dipeptidyl peptidase-4 inhibitor does not increase the risk for heart failure hospitalization.

Heart failure is a "revolving door" problem for hospitals.

Light or moderate alcohol intake has been associated with health benefits such as reduced risk of cardiovascular events, but these benefits disappear as intake increases.

Patients with heart failure often receive clopidogrel and angiotensin-converting enzyme inhibitors concurrently.

Of the 5.7 million Americans who have heart failure, about 10% progress to advanced Stage D.

A new prognostic model could help clinicians prioritize risk factors in heart failure patients.

Thiazide diuretics are the least expensive antihypertensive drugs available in most countries.

Americans make many assumptions about aging, and health care providers are no exception.

Today's approval of Amgen's ivabradine makes it the first new chronic heart failure medicine that has been approved by the FDA in almost a decade.

An FDA advisory panel recommends adding a warning about the potential risk for heart failure to the labels of saxagliptin (Onglyza), saxagliptin/metformin (Kombiglyze), and alogliptin (Nesina).

Pharmacists can improve a patient's medication adherence by dispensing information beyond a drug's label.

Readmission rates among patients with heart failure, acute myocardial infarction, and pneumonia increase when psychiatric illness is also present.

Veterans with post-traumatic stress disorder face greater odds of developing heart failure.

The FDA recently granted priority review to Novarits' investigational drug LCZ696, a potential treatment for heart failure with ejection fraction.

In celebration of Heart Failure Awareness Week, the American Heart Association would like to recognize Amgen for their support of the AHA's Get With The Guidelines®-Heart Failure initiative. Amgen's support will help achieve the goal of improving care for heart failure by helping to educate physicians and patients about consistent adherence to the latest evidence-based treatment guidelines.

Digoxin is associated with a 71% increased risk of death and a 63% higher risk of hospitalization among adults diagnosed with atrial fibrillation who have no evidence of heart failure.

When association is association and causation is causation.

Approximately 6.5 million Americans are prescribed digoxin, a cardiac glycoside with a long, fascinating history.

New late-stage trial data show ivabradine reduces cardiovascular death or hospitalization for worsening chronic heart failure in patients with low systolic blood pressure.

Patients who receive statins soon after acute coronary syndrome are 24% less likely to experience unstable angina after 4 months.

PARADIGM-HF study results offer insight into a new heart failure treatment mechanism, neprilysin inhibition.

Hospitalization rates for heart disease and stroke have dropped significantly over the past decade.